CN115531463A - 一种治疗高脂血症的中药 - Google Patents
一种治疗高脂血症的中药 Download PDFInfo
- Publication number
- CN115531463A CN115531463A CN202211343856.XA CN202211343856A CN115531463A CN 115531463 A CN115531463 A CN 115531463A CN 202211343856 A CN202211343856 A CN 202211343856A CN 115531463 A CN115531463 A CN 115531463A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- extract
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 9
- 239000006187 pill Substances 0.000 claims abstract description 35
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 28
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 28
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 23
- 241000132012 Atractylodes Species 0.000 claims abstract description 22
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims abstract description 22
- 241000208688 Eucommia Species 0.000 claims abstract description 22
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 21
- 241000729173 Cirsium japonicum Species 0.000 claims abstract description 20
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 20
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 143
- 239000000284 extract Substances 0.000 claims description 104
- 239000000843 powder Substances 0.000 claims description 69
- 238000002156 mixing Methods 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 15
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 11
- 241000180649 Panax notoginseng Species 0.000 claims description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 241000218202 Coptis Species 0.000 claims description 8
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000002555 Citrus medica var sarcodactylis Nutrition 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 229940126680 traditional chinese medicines Drugs 0.000 claims description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 5
- 239000007864 aqueous solution Substances 0.000 claims 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 2
- 239000000706 filtrate Substances 0.000 description 41
- 238000001914 filtration Methods 0.000 description 31
- 239000012530 fluid Substances 0.000 description 26
- 238000001035 drying Methods 0.000 description 16
- 244000132619 red sage Species 0.000 description 15
- 238000010298 pulverizing process Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000003809 water extraction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 4
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 229930013930 alkaloid Natural products 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- NXJCRELRQHZBQA-UHFFFAOYSA-N 5,7-dimethoxy-1-benzopyran-2-one Chemical compound C1=CC(=O)OC2=CC(OC)=CC(OC)=C21 NXJCRELRQHZBQA-UHFFFAOYSA-N 0.000 description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- LLPWNQMSUYAGQI-QBQUQATFSA-N Ginsenoside R1 Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 LLPWNQMSUYAGQI-QBQUQATFSA-N 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OAXKIRPCKWQWOQ-UHFFFAOYSA-N atractylenolide III Natural products CC1=C2CC3C(CCCC3=C)CC2(O)OC1=O OAXKIRPCKWQWOQ-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- OOTMSKDHDITFHF-UHFFFAOYSA-N cyclotetracosane Chemical compound C1CCCCCCCCCCCCCCCCCCCCCCC1 OOTMSKDHDITFHF-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000010015 huanglian Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- LLPWNQMSUYAGQI-OOSPGMBYSA-N notoginsenoside R1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)CO2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LLPWNQMSUYAGQI-OOSPGMBYSA-N 0.000 description 1
- JURZHOVRCOWZFN-UHFFFAOYSA-N notoginsenoside R1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5C(CC34C)OC6OC(COC7OCC(O)C(O)C7O)C(O)C(O)C6O)C JURZHOVRCOWZFN-UHFFFAOYSA-N 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229930193884 teucrin Natural products 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗高脂血症的中药,其原料药由下列重量份配比的中药材组成:酒女贞子10‑50份,佛手10‑30份,麸炒白术15‑40份,盐杜仲10‑30份,三七1‑20份,丹参10‑30份,大蓟5‑25份,黄连1‑20份;所述中药为浓缩丸。具有毒性低、吸湿性低、成丸性能好的优点。
Description
技术领域
本发明专利属于中药领域,具体涉及一种治疗高脂血症的中药。
背景技术
在前期的“复方贞术调脂方”大量研究中,在临床中能有效治疗高脂血症,全方由女贞子、白术、佛手、杜仲、大蓟、丹参、黄连、三七8味中药组成。方中重用女贞子,养肝肾之阴为君药;白术益气健脾、燥湿利水,以祛痰浊,与女贞子相配,则脾肾双补;杜仲补益肾阳,与女贞子相配,双补肾之阴阳,共成水火既济之剂,使补肾之效尤著,而无滋腻或助火之虞;佛手能舒肝理气、燥湿化痰,善清血中之痰浊,使气机调畅。与白术相配,理气化痰祛湿之效尤著。与白术、杜仲共为臣药;大蓟凉血祛瘀解毒;丹参活血祛瘀兼养血;三七散瘀止血不留瘀;黄连一味兼具清热燥湿解毒之功效,共为佐药。诸药合用,集健脾益肾、舒肝理气、清热化痰、祛瘀解毒功效于一方。温凉并济,扶正祛邪并举,全方补中有行,补而不腻,祛邪而不伤正气,使“虚”、“郁”、“痰”、“瘀”、“毒”得解,诸症可愈。该中药组方已获国家发明专利授权,专利号:ZL200410051250.4。
在后续的研究中,CN1259935C公开了复方贞术调脂方可以是取中药原料的提取物如水提物或醇提物或水提醇沉的提取物,或部分中药的提取物加部分中药的药粉制成药剂。如将全部中药材通过常规的中药水提工艺或水提醇沉工艺取水溶部位或醇回流提取工艺获得的提取物,进一步制成制剂,或将中药材女贞子、大蓟、白术、丹参、杜仲、黄连取提取物,将佛手、三七直接磨成细粉加入制成药剂。或者部分水提加药粉组,或者全部醇提或水提醇沉。复方贞术调脂方还进一步用于骨质疏松、痛风高尿酸、动脉硬化等治疗(CN102133222A、CN102266415A、CN113368165A),CN102091083A公开了将原料药三七和女贞子进行C1-3醇提,得到C1-3醇提物,将大蓟、白术、丹参、杜仲、佛手和黄连进行水提、浓缩,得到水提物,合并C1-3醇提物和水提物得到总提取物,再用有机溶剂萃取制备得到包含有效成分为腊醇、β-谷甾醇、正二十六烷酸、白术内酯Ⅲ、齐墩果酸、小檗碱、药根碱、黄连碱、丹参素、丹酚酸B、环二十四烷、9,12-十八碳二烯酸、5,7-二甲氧基香豆素、特女贞苷、人参皂苷Rb1和Rg1、三七皂苷R1、杜仲醇的有效部位。并进一步公开了将有效部位制成片剂、胶囊、丸剂,其中片剂采用有效部位提取物加淀粉、羧甲基纤维素,混匀,加75%酒精制粒,加硬脂酸镁压片;胶囊采用有效部位提取物淀粉、羧甲基纤维素,混合均匀后干法制粒,装胶囊。丸剂采用有效部位提取物加淀粉、糊精、蜂蜜泛丸成水蜜丸,干燥制得丸剂。
然而上述方法,将中药提取成有效部位或有效成分制成的中药复方制剂并不符合中医药配伍本来目的和作用,而且可能带来潜在的副作用,如黄连提取物会造成小鼠产生明显的急性毒性,毒性物质基础主要为各种生物碱成分;另外,研究显示,富含生物碱的提取物比黄连总提取物毒性大得多,在接受黄连的口服总提取物的小鼠的脑,心脏和肺组织中检测到四种黄连生物碱。另一方面,如果采用全方水提,虽然能符合传统中医药水煎服用的惯例,但其水提物的吸湿性等问题,都对工业级生产的产品质量和用药安全性产生不利影响,相应水提物一次服用量大,也对患者治疗过程中的顺应性不同,不易服用。因此,在前期应用研究的基础上,面对上述缺陷,仍需提供一种适应性好、安全、稳定的中药产品。
发明内容
本发明旨在解决目前复方贞术调脂方水提制剂不稳定,适应性差的问题,同时提供一种安全、有效,质量稳定的中药,具有毒性低、吸湿性低、成丸性能好的优点。
第一方面,本发明提供一种治疗高脂血症的中药,其原料药由下列重量份配比的中药材组成:酒女贞子10-50份,佛手10-30份,麸炒白术15-40份,盐杜仲10-30份,三七1-20份,丹参10-30份,大蓟5-25份,黄连1-20份;所述中药为浓缩丸。
进一步优选,其原料药由下列重量份配比的中药材组成:酒女贞子10-30份,佛手10-20份,麸炒白术15-30份,盐杜仲10-20份,三七5-15份,丹参15-30份,大蓟5-15份,黄连1-15份。
进一步优选,其原料药由下列重量份配比的中药材组成:酒女贞子10-30份,佛手10-15份,麸炒白术15-20份,盐杜仲10-15份,三七7-10份,丹参15-20份,大蓟5-10份,黄连5-8份。
第二方面,本发明提供一种第一方面的治疗高脂血症的中药的制备方法,所述方法是将原料药中酒女贞子和黄连共同用乙醇溶液提取,三七单独乙醇溶液提取,佛手、麸炒白术、盐杜仲、丹参和大蓟用水提取,在将上述三种提取物合并混合制成全方提取物干膏粉。
所述乙醇溶液为10-90%的乙醇水溶液,优选40-80%的乙醇水溶液,更优选50%、60%、70%的乙醇水溶液。
优选其中先将酒女贞子和黄连的乙醇提物和佛手、麸炒白术、盐杜仲、丹参和大蓟的水提物合并混合制成干膏粉,然后再与三七乙醇提取物干膏粉混合。
优选,将女贞子、黄连加50-90%乙醇加热回流提取2次,合并两次滤液,然后减压回收乙醇,浓缩得清膏1;
将白术、杜仲、佛手、丹参、大蓟加水提取2次,过滤,取滤液,合并两次滤液,然后减压回收乙醇,浓缩得清膏2;
将清膏1、2合并混合搅拌均匀,然后减压干燥得干膏,然后粉碎制得干膏粉A。
将三七加40-80%乙醇加热回流提取2次,合并两次滤液,然后减压回收乙醇,浓缩得清膏,将该清膏减压干燥得干膏,然后粉碎制得干膏粉B。
最后,将干膏粉A和干膏粉B混匀,制得全方提取物干膏粉。
进一步优选:
将女贞子、黄连加80%乙醇加热回流提取2次,第一次加入12倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入10倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏1。
将白术、杜仲、佛手、丹参、大蓟加水提取2次,第一次加入10倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入8倍量水提取1h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏2。
将清膏1、2合并混合搅拌均匀,然后在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉A。
将三七加60%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏,将该清膏在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉B。
最后,将干膏粉A和干膏粉B混匀,制得全方提取物干膏粉。
第三方面,本发明提供一种中药,其包括上述全方提取物干膏粉和辅料。
本发明的中药进一步制成丸剂,进一步包括制备丸剂的辅料。
优选将上述全方提取物干膏粉加入赋形剂微晶纤维素、乳糖、糊精、可溶性淀粉的一种或多种后,混合挤压制丸,制备得到浓缩丸。
其中所述干膏粉与所述赋形剂的重量比为1:(0.1-10),优选1:1,1:0.5,1:2,1:4。所述赋形剂优选微晶纤维素。
同时本发明包括适量的粘合剂,所述粘合剂选自水、乙醇溶液、PVP中的一种或多种
第四方面,本发明还提供一种中药浓缩丸的制备方法,将原料药中酒女贞子和黄连共同用乙醇溶液提取,三七单独乙醇溶液提取,佛手、麸炒白术、盐杜仲、丹参和大蓟用水提取,在将上述三种提取物合并混合制成全方提取物干膏粉;再将所述全方提取物干膏粉加入赋形剂微晶纤维素、乳糖、糊精、可溶性淀粉的一种或多种后,混合挤压制丸,制备得到浓缩丸。
第五方面,本发明还提供上述中药在制备治疗高血脂和/或非酒精性脂肪肝药物的用途。
实施例1:
中药原料药:酒女贞子450g、佛手375g、盐杜仲300g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连150g。按下列制备步骤:
将女贞子、黄连加80%乙醇加热回流提取2次,第一次加入12倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入10倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏1。
将白术、杜仲、佛手、丹参、大蓟加水提取2次,第一次加入10倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入8倍量水提取1h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏2。
将清膏1、2合并混合搅拌均匀,然后在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉A。
将三七加60%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏,将该清膏在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉B。
最后,将干膏粉A和干膏粉B混匀,制得全方提取物干膏粉。
实施例2:
中药原料药:酒女贞子400g、佛手250g、盐杜仲400g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连200g。具体制备方法同实施例1。
实施例3:
中药原料药:酒女贞子600g、佛手375g、盐杜仲600g、麸炒白术650g三七250g、丹参150g、大蓟125g和黄连150g。具体制备方法同实施例1。
实施例4:
中药原料药:酒女贞子150g、佛手600g、盐杜仲120g、麸炒白术650g三七450g、丹参250g、大蓟325g和黄连50g。具体制备方法同实施例1。
对比例1
中药原料药:酒女贞子450g、佛手375g、盐杜仲300g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连150g。按下列制备步骤:
将女贞子、黄连、三七、白术、杜仲、佛手、丹参、大蓟加水提取2次,第一次加入12倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入9倍量水提取1.5h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏,将该清膏在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉B,制得全方提取物干膏粉。
对比例2
中药原料药:酒女贞子450g、佛手375g、盐杜仲300g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连150g。按下列制备步骤:
将女贞子加70%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏1。
将白术、杜仲、佛手、丹参、大蓟加水提取2次,第一次加入12倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入9倍量水提取1.5h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏2。
将清膏1、2合并混合搅拌均匀,然后在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉A。
将黄连、三七加50%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏,将该清膏在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉B。
最后,将干膏粉A和干膏粉B混匀,制得全方提取物干膏粉。
对比例3
中药原料药:酒女贞子450g、佛手375g、盐杜仲300g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连150g。按下列制备步骤:
将女贞子、黄连、三七加70%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏1。
将白术、杜仲、佛手、丹参、大蓟加水提取2次,第一次加入12倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入9倍量水提取1.5h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏2。
将清膏1、2合并混合搅拌均匀,然后在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得全方提取物干膏粉。
对比例4
中药原料药:酒女贞子450g、佛手375g、盐杜仲300g、麸炒白术450g三七150g、丹参375g、大蓟225g和黄连150g。按下列制备步骤:
将女贞子、黄连、白术加70%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏1。
将杜仲、佛手、丹参、大蓟加水提取2次,第一次加入12倍量水,提取1.5h,然后过滤,取滤液,滤渣继续加入9倍量水提取1.5h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏2。
将清膏1、2合并混合搅拌均匀,然后在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉A。
将三七加50%乙醇加热回流提取2次,第一次加入10倍量乙醇,提取2h,然后过滤,取滤液,滤渣继续加入8倍量乙醇提取2h,过滤,取滤液,合并两次滤液,然后在真空度-0.6MPa,温度60-70℃减压回收乙醇,浓缩得清膏,将该清膏在真空度-0.8MPa,温度60-70℃减压干燥得干膏,然后粉碎制得干膏粉B。
最后,将干膏粉A和干膏粉B混匀,制得全方提取物干膏粉。
实验例1
急性毒性试验
将小鼠分成5组,每组30只,雌雄各半,每组分别给予实施例1、对比例1-4的药物(将实施例1、对比例1-4的干膏粉加入水混匀制成相同浓度药液)。给药前,小鼠禁食不禁水12h,每天灌胃给药一次,观察给药7天内小鼠死亡情况。
表1急性毒性试验结果
急性毒性试验结果表明,全方水提具有较好的安全性,将黄连和酒女贞子乙醇共提,三七单独乙醇提取,其它药味水提也具有较好的安全性。而将黄连同其它药味共同提取,毒性有所增加。这可能黄连和女贞子在乙醇溶液共提中,提取的有效成分发生相互作用,减小了黄连的毒性,两者之间可能存在药对配伍,发生减毒增效的作用。
实施例5
取实施例1制备得到全方提取物干膏粉,将上述干膏粉和微晶纤维素按重量1:1的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例6
取实施例1制备得到全方提取物干膏粉,将上述干膏粉和微晶纤维素按重量1:1.5的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例7
取实施例1制备得到全方提取物干膏粉,将上述干膏粉、微晶纤维素和糊精按重量1:0.5:0.5的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例8
取实施例1制备得到全方提取物干膏粉,将上述干膏粉、乳糖和可溶性淀粉按重量1:0.5:0.5的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例9
取实施例1制备得到全方提取物干膏粉,将上述干膏粉、乳糖按重量1:1的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例10
取对比例1制备得到全方提取物干膏粉,将上述干膏粉、微晶纤维素按重量1:1的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例11
取对比例1制备得到全方提取物干膏粉,将上述干膏粉、微晶纤维素和糊精按重量1:0.5:0.5的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例12
对比例1制备得到全方提取物干膏粉,将上述干膏粉、乳糖和可溶性淀粉按重量1:0.5:0.5的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实施例13
取对比例1制备得到全方提取物干膏粉,将上述干膏粉、乳糖按重量1:1的比例充分混合,然后加入适量的粘合剂如1%的PVP30溶液,制成软材,然后用挤出法制丸,定形,抛丸,60℃以下干燥,包装,即得浓缩丸。
实验例2
吸湿性实验
配置相对湿度为75%的饱和氯化钠溶液,在25℃室温环境下形成恒温恒湿环境。然后将实施例5、7-13的浓缩丸分别放置恒重的称量瓶中,每组3份,精密称定。分别于72h、144h精密称定样品质量,计算吸湿率。其中吸湿率=(吸湿后粉末重量-吸湿前粉末重量)/吸湿前粉末重量*100%。结果见表2.
表2吸湿率结果
结果表明,全方水提物的吸湿性较大,不适宜长期贮存。且乳糖、微晶纤维素作为辅料能有效降低吸湿率。
实验例3
分别取实施例5、7-9制备过程的丸条,采用质构曲线解析方法(GHUP)测定丸条的压缩力、咀嚼性、内聚性,所采用的测定仪器为TX-XTplus物性测定仪,其中压缩力表征丸条的硬度;咀嚼性则表征丸条的成球性,咀嚼性越大,则越难搓制成丸粒,成球性越差;内聚性,内聚性越大,制丸时出现裂丸、碎丸的概率越低。结果见表3。
表3测定结果
压缩力g | 咀嚼性g.s | 内聚性g | |
实施例5 | 65.8 | 316.7 | -45.6 |
实施例7 | 156.7 | 521.1 | -86.7 |
实施例8 | 287.2 | 468.3 | -93.1 |
实施例9 | 342.1 | 682.4 | -142.7 |
结果表明,相比其它辅料,采用微晶纤维作为本发明浓缩丸的辅料,更易制丸、成球,裂丸、碎丸也较少。
实验例4
溶散时限
按照2020版药典规定,取实施例5、7-9供试品各6丸,选择适当孔径筛网的吊篮(丸剂直径在2.5mm以下的用孔径约0.42mm的筛网;在2.5~3.5mm之间的用孔径约1.0mm的筛网;在3.5mm以上的用孔径约2.0mm的筛网),照崩解时限检查法(通则0921)片剂项下的方法加挡板进行检查。
表4溶散时限结果
组别 | 溶散时限min |
实施例5 | 26 |
实施例7 | 41 |
实施例8 | 46 |
实施例9 | 28 |
结果表明,实施例5的处方具有较好的溶散效果。
实验例5
取大鼠30只,随机分成3组:正常对照组、模型组、实施例5组。正常对照组给予常规饲料,其余2组用高脂饲料喂养制备高血脂模型。造模成功后,模型组给予正常饲料,实施例5组连续给药14天后,摘下眼球取血,以酶法测定大鼠血清总胆固醇(TC),血清甘油三脂(TG)。
表5降血脂实验结果
组别 | TC mmol/L | TG mmol/L |
正常对照组 | 2.02±0.18 | 0.89±0.17 |
模型组 | 8.13±0.43 | 3.19±0.21 |
实施例5 | 4.35±0.32 | 1.57±0.25 |
Claims (10)
1.一种治疗高脂血症的中药,其特征在于,其原料药由下列重量份配比的中药材组成:酒女贞子10-50份,佛手10-30份,麸炒白术15-40份,盐杜仲10-30份,三七1-20份,丹参10-30份,大蓟5-25份,黄连1-20份;所述中药为浓缩丸。
2.根据权利要求1所述的中药,其特征在于,其原料药由下列重量份配比的中药材组成:酒女贞子10-30份,佛手10-20份,麸炒白术15-30份,盐杜仲10-20份,三七5-15份,丹参15-30份,大蓟5-15份,黄连1-15份。
3.根据权利要求1所述的中药,其特征在于,将原料药中酒女贞子和黄连共同用乙醇溶液提取,三七单独乙醇溶液提取,佛手、麸炒白术、盐杜仲、丹参和大蓟用水提取,在将上述三种提取物合并混合制成全方提取物干膏粉。
4.根据权利要求3所述的中药,其特征在于,将所述全方提取物干膏粉加入赋形剂微晶纤维素、乳糖、糊精、可溶性淀粉的一种或多种后,混合挤压制丸,制备得到浓缩丸。
5.根据权利要求4所述的中药,其特征在于,其中所述干膏粉与所述赋形剂的重量比为1:(0.1-10),优选1:1。
6.根据权利要求4所述的中药,其特征在于,所述赋形剂为微晶纤维素。
7.根据权利要求3所述的中药,其特征在于,所述乙醇溶液为10-90%的乙醇水溶液,优选40-80%的乙醇水溶液,更优选50%、60%、70%的乙醇水溶液。
8.根据权利要求3所述的中药,其特征在于,其中先将酒女贞子和黄连的乙醇提物和佛手、麸炒白术、盐杜仲、丹参和大蓟的水提物合并混合制成干膏粉,然后再与三七乙醇提取物干膏粉混合。
9.根据权利要求1所述的中药的制备方法,其特征在于,将原料药中酒女贞子和黄连共同用乙醇溶液提取,三七单独乙醇溶液提取,佛手、麸炒白术、盐杜仲、丹参和大蓟用水提取,在将上述三种提取物合并混合制成全方提取物干膏粉;再将所述全方提取物干膏粉加入赋形剂微晶纤维素、乳糖、糊精、可溶性淀粉的一种或多种后,混合挤压制丸,制备得到浓缩丸。
10.根据权利要求1-8任意一项所述的中药在制备治疗高血脂和/非酒精性脂肪肝药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211343856.XA CN115531463B (zh) | 2022-10-31 | 2022-10-31 | 一种治疗高脂血症的中药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211343856.XA CN115531463B (zh) | 2022-10-31 | 2022-10-31 | 一种治疗高脂血症的中药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115531463A true CN115531463A (zh) | 2022-12-30 |
CN115531463B CN115531463B (zh) | 2024-03-08 |
Family
ID=84719094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211343856.XA Active CN115531463B (zh) | 2022-10-31 | 2022-10-31 | 一种治疗高脂血症的中药 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115531463B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116898912A (zh) * | 2023-07-12 | 2023-10-20 | 广东药科大学 | 一种复合中药在制备防治糖尿病脑病药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628786A (zh) * | 2004-08-30 | 2005-06-22 | 广东药学院 | 一种治疗高脂血症的药物 |
CN102078418A (zh) * | 2011-01-14 | 2011-06-01 | 广东药学院 | 一种防治脂代谢紊乱的复方中药提取物及其制备方法 |
-
2022
- 2022-10-31 CN CN202211343856.XA patent/CN115531463B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1628786A (zh) * | 2004-08-30 | 2005-06-22 | 广东药学院 | 一种治疗高脂血症的药物 |
CN102078418A (zh) * | 2011-01-14 | 2011-06-01 | 广东药学院 | 一种防治脂代谢紊乱的复方中药提取物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
谢蓉蓉 等: "复方贞术调脂方化学成分研究(Ⅰ )", 广东药学院学报, vol. 26, no. 4, pages 331 - 333 * |
黎珊珊 等: "近红外光谱技术快速测定黄连女贞子提取过程中2 种成分含量", 广东化工, vol. 45, no. 10, pages 33 - 35 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116898912A (zh) * | 2023-07-12 | 2023-10-20 | 广东药科大学 | 一种复合中药在制备防治糖尿病脑病药物中的应用 |
CN116898912B (zh) * | 2023-07-12 | 2024-05-03 | 广东药科大学 | 一种复合中药在制备防治糖尿病脑病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN115531463B (zh) | 2024-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104383123A (zh) | 一种金花茶降脂降糖制剂的制备方法 | |
WO2013071727A1 (zh) | 抗肿瘤的中药组合物 | |
CN106924374B (zh) | 一种组合物及其制备方法与在制备降血糖和/或降血脂的产品中的应用 | |
CN115531463B (zh) | 一种治疗高脂血症的中药 | |
CN113663029A (zh) | 复方金荞麦组合物 | |
CN111905051A (zh) | 具有防治慢性心衰气阴两虚血瘀水停证作用的中药组合物及其制备方法与应用 | |
CN102961584A (zh) | 一种抗疲劳的中药组合物及其制备方法和应用 | |
CN111588757A (zh) | 一种治疗慢性阻塞性肺疾病稳定期的中药组合物及制备方法 | |
CN107997170B (zh) | 一种具有降血脂功能的组合物及其制备方法 | |
CN111253459B (zh) | 一种三七皂苷炮制品及其制备方法和应用 | |
CN107929512B (zh) | 一种采用超高压提取制备龙牡壮骨颗粒的方法 | |
WO2022057498A1 (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
CN105125616A (zh) | 一种提高缺氧耐受力的中药组合物 | |
CN100506219C (zh) | 一种三七止血药的制备方法 | |
CN112704723A (zh) | 一种治疗妇科痛经的中药制剂及其制法 | |
CN105125898A (zh) | 一种含黄芪和天麻具有益气补血的药物制剂 | |
CN103816466A (zh) | 一种治疗胸痹心痛的中药组合物及其制剂和制备方法 | |
CN104587300A (zh) | 用于治疗急性白血病的中药组合物及其制备方法 | |
CN106466396B (zh) | 一种妇科调经缓释滴丸及其制备方法 | |
CN104189833A (zh) | 一种逍遥丸的制备工艺 | |
CN104547027B (zh) | 一种丹参叶三七叶提取物的制备方法及其应用 | |
CN103494916A (zh) | 一种具有降低血糖功效的中药组合物及其制备方法和应用 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
CN114533819B (zh) | 一种用于治疗高血脂症的中药组合物及其制备方法和应用 | |
CN112057536B (zh) | 一种预防或/和治疗血脂异常的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |